



Date: 06.02.2026

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001.

Ref: Scrip Code: 526075

Sub: Outcome of the Board Meeting held on 06th February, 2026

Dear Sir/Madam,

Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 6th February, 2026 has inter-alia adopted and approved

- 1) The Standalone Un-Audited Financial Results for the Quarter and Nine months ended on 31st December, 2025.
- 2) Limited Review Report by Statutory Auditors of the Company on Standalone Un-Audited Financial Results for the Quarter and Nine months ended on 31st December, 2025.

The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 05:32 P.M.

This is for your information and record

Thanking you,

For Rekvina Laboratories Limited

Deepak Khandelwal
Company Secretary

CIN: L24231GJ1988PLC01145

Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -39007

Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com

Cont. No.: 0265-2362966

REKVINA LABORATORIES LIMITED
CIN: L24231GJ1988PLC011458
Standalone Financial Result for the period ended on 31 December 2025

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Nine months ended		Year Ended
		31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	Income						
	Revenue From Operations	34.56	19.62	-	54.18	-	-
	Total Income (I)	34.56	19.62	-	54.18	-	-
II	Expenses						
	Purchases of Stock-in-Trade	33.06	17.84	-	50.90	-	-
	Employee benefits expense	10.11	3.77	0.95	16.58	0.95	4.30
	Other expenses	3.78	1.50	1.48	6.12	8.48	9.41
	Total expenses (II)	46.95	23.11	2.43	73.60	9.43	13.71
III	Profit/(loss) before tax (I-II)	(12.39)	(3.49)	(2.43)	(19.42)	(9.43)	(13.71)
IV	Tax expense						
	Current tax	-	-	-	-	-	-
	Total Tax expense (IV)	-	-	-	-	-	-
V	Profit/(loss) after tax for the period (III-IV)	(12.39)	(3.49)	(2.43)	(19.42)	(9.43)	(13.71)
VI	Other Comprehensive Income						
	Total Other Comprehensive Income (VI)	-	-	-	-	-	-
VII	Total Comprehensive Income for the period (V+VI)	(12.39)	(3.49)	(2.43)	(19.42)	(9.43)	(13.71)
VIII	Earnings per equity share						
	Basic	(0.21)	(0.06)	(0.04)	(0.32)	(0.16)	(0.23)
	Diluted	(0.21)	(0.06)	(0.04)	(0.32)	(0.16)	(0.23)

- 1 The Above Standalone Quarterly Financial Results have been reviewed and recommended by the Audit Committee and the same has been approved by the Board of Directors of the Company at its meeting held on 06-02-2026.
- 2 As the Company's business activity falls within a single primary business segment, namely dealing in Trading of Pharma Goods, the disclosure requirements as per Ind-AS 108 "operating segments" are not applicable.
- 3 The Earing Per Shares has been computed in accordance with Accounting Standard on Earing Per Shares (AS 20).
- 4 Previous period figures have been regrouped/reclassified wherever necessary to confirm with the current periods classification/disclosure.
- 5 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IND AS) prescribed under section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standard) Rules, 2016 and Companies (Indian

For and on behalf of Board of Directors,
Rekvina Laboratories Limited

Place: Vadodara
Date: 06.02.2026

Mr. Amit Mukesh Shah
Managing Director
DIN: 01993211

Independent Auditor's Review Report on the Quarter Ended Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to The Board of Directors

Rekvina Laboratories Limited.


1. We have reviewed the accompanying statement of unaudited standalone financial results of Rekvina Laboratories Limited (the "Company") for the 3rd quarter Ended 31th December 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/44/2019, dated 29-03-2019. (The Circular).
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2013 read with SEBI Circular No. CIR/CFD/CMD1/44/2019, is the responsibility of the Company's management and has been taken on record by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2014, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.
5. The accompanying IND AS financial results and other financial information for the corresponding quarter ended 30-09-2025, have been subject to a limited review or audit and based on the information compiled by Management and has been taken on record by the Board of Directors.

Date: 06.02.2026

Place: Vadodara

FOR Y. M. SHAH & Co.
Chartered Accountants
F. R. No.: 114124W




Yogesh Shah
Partner
M. No. 044305
UDIN: 26044305RYOBLF2729